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Editor’s key points
† Most studies of diabetic
neuropathy use rat
models of type I diabetes.
† This study used a more
relevant model of type II
diabetes.
† Sciatic nerve bock
duration and
neurotoxicity were
studied.
† Motor block was
prolonged in rats with
neuropathy, but there was
no evidence of nerve
injury.
Background. The neuropathy of type II diabetes mellitus (DM) is increasing in prevalence
worldwide. We aimed to test the hypothesis that in a rodent model of type II DM,
neuropathy would lead to increased neurotoxicity and block duration after lidocaine-
induced sciatic nerve block when compared with control animals.
Methods. Experiments were carried out in Zucker diabetic fatty rats aged 10 weeks (early
diabetic) or 18 weeks (late diabetic, with or without insulin 3 units per day), and age-
matched healthy controls. Left sciatic nerve block was performed using 0.2 ml lidocaine
2%. Nerve conduction velocity (NCV) and F-wave latency were used to quantify nerve
function before, and 1 week after nerve block, after which sciatic nerves were used for
neurohistopathology.
Results. Early diabetic animals did not show increased signs of nerve dysfunction after
nerve block. In late diabetic animals without insulin vs control animals, NCV was 34.8 (5.0)
vs 41.1 (4.1) ms s21 (P,0.01), and F-wave latency was 7.7 (0.5) vs 7.0 (0.2) ms (P,0.01),
respectively. Motor nerve block duration was prolonged in late diabetic animals, but
neurotoxicity was not. Late diabetic animals receiving insulin showed intermediate results.
Conclusions. In a rodent type II DM model, nerves have increased sensitivity for short-acting
local anaesthetics without adjuvants in vivo, as evidenced by prolonged block duration. This
sensitivity appears to increase with the progression of neuropathy. Our results do not support
the hypothesis that neuropathy due to type II DM increases the risk of nerve injury after nerve
block.
Keywords: local anaesthetics; nerve block; neuropathy, diabetic; neurotoxicity
Accepted for publication: 21 May 2014
Diabetic peripheral neuropathy (DPN) is a frequent complica-
tion of both type I and type II diabetes mellitus (DM), and the
most prevalent neuropathy in the Western world.1 Diabetics
undergo surgery more often than non-diabetic patients,2 and
several surgical procedures for typical complications of long-
standing DM, for example, creation of arteriovenous fistula in
patients with end-stage renal disease, might be preferably per-
formed under regional anaesthesia.3
However, diabetic neuropathic nerves may be more sensi-
tive to local anaesthetics and their toxicity, and this hypothesis
is supported by two lines of evidence. First, regional anaesthe-
sia in diabetic neuropathic patients may be associated with
increased risk of neurological injury.4 Limited epidemiological
evidence suggests higher risk of neurotoxicity in diabetic
neuropathic patients,5 6 even if experimental evidence has
been equivocal.7 Secondly, DPN may influence nerve block dur-
ation.4 Clinical8 9 and experimental10 11 evidence suggests that
block duration may be prolonged in diabetic neuropathic
nerves. However, most studies were carried out in models of
streptozotocin-induced type I DM, which does not reflect clin-
ical reality, in which the huge majority of patients suffer from
type II DM.5 7
Our aim was to determine the impact of regional anaesthe-
sia in DPN in an animal model for type II DM. We therefore
sought to devise a comprehensive model using behavioural,
electrophysiological, and histopathological investigations to
determine neurotoxicity of a lidocaine 2% peripheral nerve
block and duration of this nerve block in Zucker diabetic fatty
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(ZDF) rats with early and advanced diabetic neuropathy, with
and without partial glycaemic control. Our working hypothesis
was that in a rodent model of type II DM, the presence of
advanced (18 weeks) but not early (10 weeks) neuropathy
would lead to increased neurotoxicity and block duration
after sciatic nerve block with lidocaine when compared with
age-matched healthy control animals. The primary endpoint
was neurohistopathology 1 week after nerve block.
Methods
The study protocol was approved by the Institutional Animal
Care and Use Committee of the Academic Medical Center,
University of Amsterdam, protocol number LEICA102868-1.
Methods and results are reported according to relevant ARRIVE
guidelines.12
Animals
Experiments were undertaken in ZDFrats, which were obtained
from Charles River Laboratories (L’Arbresle, France). This inbred
model of type II DM combines a genetic predisposition (homo-
zygous leptin receptor mutation fa/fa, ‘diabetic’, or heterozy-
gous mutation fa/+, ‘control’) with a dietetic component
(Purina #5008 diet, Charles River, L’Arbresle, France).11 13
Animals were obtained at 9 weeks of age and were allowed
to acclimatize for 1 week. For all electrophysiological measure-
ments, sciatic nerve block, and placement of insulin release
implants, animals were anaesthetized using isoflurane
(Baxter, Utrecht, The Netherlands) with an inspiratory concen-
tration between 2 and 3 vol%, since this regimen least affects
electrophysiological measurements in rodent models.14 Ad-
equacy of anaesthesia was ascertained by lack of a pedal with-
drawal response to a nociceptive stimulus. All procedures were
performed percutaneously, and the analgesic rescue protocol
was buprenorphine (0.05 mg kg21 body weight). Detailed
welfare assessment was undertaken by an animal care techni-
cian unrelated to the experiment. After the last measure-
ments, while still under isoflurane anaesthesia, animals were
killed using CO2 narcosis.
Experimental groups
The timeline of experimental procedures is given in Figure 1. In
all experimental groups, baseline measurements of electro-
physiological parameters (see below) were taken at 10 weeks
of age.
Group ‘early control (EC)’ were 6 ZDF fa/+ animals, and
group ‘early diabetic (ED)’ were 10 ZDF fa/fa animals undergo-
ing left sciatic nerve block immediately after baseline testing at
10 weeks. One week later, behavioural and electrophysiologic-
al measurements were repeated, and the left sciatic nerve was
excised for neurohistopathological evaluation.
The group ‘late control (LC)’ consisted of 10 fa/+ animals
kept until 18 weeks of age. The group of diabetic animals for
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Fig 1 Timeline of experimental interventions.
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the late experiments were randomized into one of the two
groups according to a predefined randomization list: group
‘late diabetic without insulin (LD)’ were 10 ZDF fa/fa diabetic
animals kept until 18 weeks of age. Group ‘late diabetic with
insulin (LDI)’ were 10 ZDF fa/fa animals, which received 1.5
s.c. insulin implants (LinPlant, LHR-10BV, LinShin, Toronto,
Canada) using a custom-made trocar G12-SS, LinShin) at 10
weeks old. These animals were dosed according to weight at
10 weeks, 300 g, and received 3 units insulin per day for a
period of 60 days, covering our experimental period.15 Groups
LC, LD, and LDI underwent further ‘late baseline’ electrophysio-
logical testing at 18 weeks of age, followed by sciatic nerve
block. One week later, behaviour and electrophysiology tests
were repeated, and tissue excision for neurohistopathology
was performed.
Serum glucose levels were measured in all animals in blood
drawn from the left tail vein, using a commercially available
glucose meter (Blue, FIA Biomed, Emsdetten, Germany),
which was regularly calibrated. In Groups EC and ED, this was
done at 10 and 11 weeks, and in Groups LC, LD, and LDI, this
was done at 10, 14, 16, and 18 weeks of age.
Electrophysiology
With temperature maintained well above 348C using a
warming blanket (HK25, Beurer, Ulm, Germany), we studied
the sciatic and caudal nerve with monopolar needle electrodes
using a Nicolet Viking IVP electromyography system (Nicolet,
Madison, WI, USA), as described previously.16 In brief, for
motor conduction studies of the sciatic nerve, the recording
cathode was placed in the intrinsic muscles between the
hallux and the second digit, and the recording anode was
placed subcutaneously on the lateral surface of the fifth digit.
Stimulating electrodes were inserted 3 mm apart at the medial
ankle, and just cranial to the sciatic notch. A grounding elec-
trode was attached between the stimulating and the recording
electrodes. Supramaximal square-wave pulses of 0.1 ms dur-
ation were delivered. Supramaximal stimulation was achieved
by increasing the intensity by 25–30% above maximal stimula-
tion. Compound muscle action potential (CMAP) amplitudes
(peak to peak) were recorded. Motor nerve conduction velocity
(NCV) was calculated over the segment between the sciatic
notch and the ankle, and minimal F-wave latency was mea-
sured from seven F-wave recordings.
For studies of the mixed sensory and motor caudal nerve,17
recording cathodes and anodes were inserted at the base of
the tail just 5 mm apart. The stimulating cathode was placed
laterally in the tail at exactly 3 cm from the base of the tail;
the stimulating anode was inserted 5 mm distal to the stimu-
lating cathode. The earth electrode was attached halfway
between the stimulating and recording electrodes. Supramax-
imal square-wave pulses of 0.5 ms duration were delivered.
Compound nerve action potential amplitudes (negative peak)
were recorded. The NCV of the tail nerve was calculated from
the latency of the stimulus artifact to the onset of the negative
peak of the action potential elicited and the distance between
the stimulating and the recording cathodes, which was a
standard distance of 3 cm. All measurements were carried
out by one investigator (P.L.), and electrophysiological mea-
surements underwent blinded assessment and validation by
an experienced neurophysiologist (C.V.).
Sciatic nerve block
Nerve block was performed percutaneously, combining the
technique described by Thalhammer and colleagues18 modi-
fied by nerve stimulation as described by Kroin and collea-
gues.10 In brief, a 25 G needle was introduced just caudal to
the sciatic notch directed cephalad, and connected with a
clip to the Viking electromyography system programmed to
delivera pulse of 0.1 ms duration, and 0.6 mA current, triggered
manually. Ipsilateral hind-leg kick in the absence of local
stimulation was taken as a sign of proximity of needle to
nerve, and injection of 0.2 ml of lidocaine 2% was performed.
We defined a successful nerve block on the basis of three signs:
(i) before injection, successful nerve stimulation at 0.6 mA
current,
(ii) gradual disappearance of the CMAP in electrophysio-
logical recordings after injection of lidocaine, and
(iii) subsequent behavioural testing showing absence of
the toe-spreading reflex.
The latter reflex, used to test sciatic nerve fibres, was tested as
described by Kroin and colleagues.10 Animals were gently
lifted, resulting in a physiological vestibular reflex where toes
are extended and spread. We noted the presence or absence
of these findings to characterize block duration every 15 min
until the block subsided. This gross behavioural testing was
repeated before the animals were subjected to anaesthesia,
1 week after nerve block to detect any permanent nerve injury.
Neurohistopathology
The main outcome parameter was the nerve injury score of the
left sciatic nerve 1 week after nerve block. To this end, after the
last electrophysiological measurements, left sciatic nerves
were excised immediately after euthanasia. The segment
proximal and distal from the site of injection was harvested,
and fixed with a 2% buffered formalin solution, embedded in
paraffin, cut at 6 mM in longitudinal and transverse sections,
and stained with haematoxylin–eosin (HE) and Masson tri-
chrome. Samples were examined under the light microscope
for evidence of inflammation in the epineurial, perineurial,
and endoneurial compartment, vascular injury, and nerve
fibre injury. Nerve fibre injury was assessed using a simple,
semi-quantitative four-point score where 0 represents a nor-
mal nerve and 4 represents extreme injury with inflammation
and destruction of all components of the nerve including axons
and myelin, extending throughout the nerve bundle.19 The path-
ologist (U.G.) was blinded to experimental group allocation.
Statistical analysis
Semi-quantitative neurohistopathological data such as the
primary outcome were compared by the Friedman test fol-
lowed—if significant—by the Mann–Whitney U-test. Power
analysis revealed that a group size of 10 animals would have
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80% power to reject the null hypothesis that the neurohisto-
pathology score in the one group is significantly different
from another group of nerves using the Mann–Whitney
U-test with a 0.05 two-sided significance level. Body weight,
blood glucose level, and neurophysiological data were com-
pared by analysis of variance (ANOVA) between the groups
followed by the post hoc Bonferroni test for multiple compari-
sons. Variations of neurophysiological data over time were
compared using the pairedT-tests.AP-value of,0.05 wascon-
sidered significant. Statistical analysis was performed with IBM
SPSSwStatistics Version 20 (IBM, San Francisco, CA, USA). Power
analysis was done with the aid of nQuery Advisorw 7.0 (Statis-
tical Solutions Ltd, Cork, Ireland).
Results
All animals survived to the end of the experiment, no animal
needed analgesic rescue, and no animal fulfilled predefined
criteria for termination of experiments (humane endpoints).
Welfare assessment showed no abnormalities concerning ap-
pearance or behaviour at any time point. All animals showed
clinical recovery from sciatic nerve block.
Early diabetes
At baseline (10 weeks), the mean glucose value was 7.1 (1.0) in
EC and 13.1 (4.9) mmol litre21 in ED animals (P,0.01). The
mean body weight was 288.8 (8.5), respectively, 344.1 (16.7) g
(P,0.001). In EC vs ED nerves, sciatic nerve MNCV was 39.3
(4.2) vs 35.7 (2.5) m s21 at baseline (P¼0.02), and minimal
F-wave latency was 7.3 (0.5) ms vs 7.9 (0.6) (P,0.005).
Sciatic nerve block duration was 45 (13) min in the EC group,
and 67.5 (27) min in the ED group (P¼0.08).
The differences between electrophysiological parameters
at baseline and 1 week after sciatic nerve block were calcu-
lated. The mean MNCV was decreased 1 week after block com-
pared with baseline across EC and ED animals (P,0.01). There
was no difference between EC and ED animals in their change
over time. We found no significant differences in electrophysio-
logical CMAP parameters for LC and EC animals at baseline and
after nerve block (Supplementary Appendix S1).
In histopathological investigations, most specimens in the
ECand ED groups showed mild chronic inflammation in the epi-
neurium and in the adipose tissue. In the EC group, one out
of six animals had a minimally elevated nerve injury score of
‘1+’ (out of 4), compared with three out of 10 animals in the
ED group with an elevated nerve injury score of ‘1+’ (n¼1)
and ‘2+’ (n¼2, NS).
Late diabetes
Weight and glucose levels of test animals are given in Table 1.
Diabetic animals were randomized at 10 weeks of age
to receive insulin treatment (LDI) or no treatment (LD). At
14 weeks of age, the mean glucose values were significantly
lower in LDI than in LD animals.However, thereafter the differ-
ence was not significant (Table 1). Neurophysiological data of
conduction velocity and minimal F-wave latency are given in
Figure 2. Conduction velocity increased over time in the LC
group, whereas it remained unaltered in LD and LDI animals.
The conduction velocity at 18 weeks in the LD animals was
significantly lower than in the LC group and remained so for
1 week after sciatic nerve block. After nerve block, conduction
velocity tended to decrease in all groups, but this decrease
neither reached statistical significance in any of the separate
groups nor when data of all groups were pooled (P¼0.15,
Fig. 2A). We found no significant differences in electrophysio-
logical CMAP parameters for LC and LD animals before and
after nerve block (data are given in Supplementary Appendix
S2). Caudal NCV was slowed significantly when comparing
animals in Groups LC [65.3 (12) m s21] and LD [57.1 (8) m s21,
P,0.05].
At 18 weeks, minimal F-wave latencies were significantly
prolonged in the LD when compared with the LC group. At
1 week after nerve block, the latency increased significantly,
when data from all three groups (LC, LD, LDI) were pooled
(Fig. 2B). Decreases in minimal F-wave latency between the
three groups were not significant.
Block duration was shortest in the LC group, longest in the LD
group, and intermediate in the LDI group (Fig. 2C). The LDI
animals had a longer block than the LC animals, but there was
no significant difference in block duration between LD and LDI
animals. LD animals had a block duration significantly longer
[94.5 (33.2) min] than ED animals [67.5 (27) min, P,0.05].
In histopathological investigations, we noted only minor
changes. LC animals showed minimal, variable, multi-focal
chronic inflammatory infiltrates in epineural connective tissue,
generallynotextending intotheendoneurialorperineurialcom-
partments. One animal out of the LDI group and one animal out
of the LD group showed focal oedema or focal area of acute
myelin injury and axonal damage, associated with scattered in-
flammatory cells. The neurohistopathological changes were not
different between the groups (Fig. 3).
Table 1 Body weight and blood glucose. Weight and blood glucose
levels of all groups over time. Tested by ANOVA with the post hoc
Bonferroni correction. NS, not significant; LC, late control; LD, late
diabetic; LDI, late diabetic with insulin
Weeks 10 14 16 18
Body weight (g)
LC (n¼10) 282 (14) 364 (17) 386 (23) 402 (37)
LD (n¼10) 345 (19) 419 (39) 427 (38) 435 (36)
LDI (n¼10) 350 (20) 471 (25) 484 (35) 494 (41)
LC vs LD P,0.001 P,0.001 P,0.05 NS
LC vs LDI P,0.001 P,0.001 P,0.001 P,0.001
LD vs LDI NS P,0.01 P,0.01 P,0.01
Blood glucose (mmol)
LC (n¼10) 7.6 (1.9) 6.0 (0.5) 6.2 (0.5) 8.1 (1.2)
LD (n¼10) 11.9 (5.3) 24.2 (5.1) 25.5 (3.2) 28.4 (3.4)
LDI (n¼10) 11.5 (4.6) 17.8 (7.4) 21.6 (5.0) 25.2 (5.5)
LC vs LD NS P,0.001 P,0.001 P,0.001
LC vs LDI NS P,0.001 P,0.001 P,0.001
LD vs LDI NS P,0.05 NS NS
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Discussion
In ZDF rats at 10 weeks of age, there was no prolongation of
duration of sciatic block with lidocaine 2% and no discernible
impact on nerve damage 1 week after sciatic nerve block. In
older rats (18 weeks), with more long-standing diabetes and
clear signs of neuropathy, sciatic nerve block duration was
substantially prolonged, but there were no gross behavioural
signs, or increased neurohistopathological evidence of nerve
injury 1 week after sciatic nerve block. Electrophysiological
changes suggestive of subtle nerve dysfunction after nerve
block were present in all experimental groups, unrelated to
the duration or severity of the neuropathy.
The ZDF rats are a model of type II DM and therefore repre-
sents the predominant patient population more accurately
than the previously used STZ-induced type I DM model.7
Notably, pathogenesis differs considerably between type I
and type II diabetes in experimental models20 and in
humans,1 and implications for regional anaesthesia should
preferably be undertaken in a model most closely resembling
the clinical situation.7 However, all previous investigations
had been conducted in models of type I DM in vivo,10 21 – 23 or
in type II DM in vitro.11 Our investigation is the first to investi-
gate the effects of a DPN secondary to type II DM on toxicology
and function of sciatic nerve block.
Early diabetes
In our model, ED rats at 10 weeks of age had mildly decreased
nerve conduction velocities, indicating mild diabetic neur-
opathy. The neuropathy in these rats develops over time and
our measurements of neuropathy correspond well with previ-
ous literature.24 Duration of nerve block was not significantly
prolonged (P¼0.08) in ED when compared with EC animals.
We found no significant neurohistopathological or gross be-
havioural signs of nerve damage 1 week after sciatic nerve
block. Our neurotoxicity results correspond to previous in vitro
investigations in the ZDF model at 12 weeks of age,11 and
with an in vivo model of type I DM.23
Late diabetes
LD animals at 18 weeks of age had decreased nerve conduction
velocities when compared with LC animals, indicating the de-
velopment of a more severe diabetic neuropathy over time,
concurring with previous literature.25 We found that while
there was a slight increase in MNCV in LC over time, the MNCV
of LD was not increased. This is in concordance with previous
work by Oltman and colleagues,24 where a slight increase in
MNCV in lean (healthy) animals over time until the 20th week
was observed. Also, we corroborated our MNCV findings bysim-
ultaneous measurements of the caudal NCV, confirming dia-
betic neuropathy also in this predominantly sensory nerve.17
We found no histopathological signs of increased neurotox-
icity in LD animals when compared with age-matched LC
animals, after lidocaine-induced sciatic nerve block. Our results
mirror previous investigations in type I DM, in which lidocaine at
clinical concentrations had limited neurotoxic effects.10 21
There have been no in vivo local anaesthetic neurotoxicity
investigations in type II diabetic models at all, but recent in
vitro data show only modest neurotoxicity of 2% lidocaine.11
Our data confirm and widen these in vitro results using multi-
faceted testing in vivo. Furthermore, epidemiological clinical
outcome data suggest that even when long-lasting local
anaesthetics are used, nerve injury after neuraxial block in
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Fig2 Development of sensible conduction velocity (A) and minimal
F-wave latency (B) over time in the three experimental groups. After
nerve block, conduction velocity tended to decline in all groups, but
did not reach statistical significance when groups were pooled
(P¼0.15). Sciatic nerve motor block duration in late diabetic
animals (C). After the nerve block, the minimal F-wave latency
increased significantly, when the data of all three groups were
pooled. Data are shown as mean and SD. ANOVA with the post hoc
Bonferroni test, pairedsamplesT-test. *P,0.05; #P,0.01; ##P,0.001.
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patients with pre-existing neuropathy is rare. Specifically, in
one retrospective study, the incidence of apparent neuropathic
complications after neuraxial anaesthesia was two in 325
patients.6 Across the past 20 yr, six case reports describing as-
sociation of nerve damage with diabetic neuropathy after re-
gional anaesthesia have been published.5
We note highly significant prolongation of minimal F-wave
latency as a subtle marker of nerve dysfunction 1 week after
sciatic nerve block. This has not been previously described,
but there was no difference between LD and LC animals, such
that this most likely represents a minor and unspecific sequel
of nerve block. The clinical importance of this remains
unclear, and is most probably very limited. There has been dis-
cussion whether regional anaesthesia in diabetic patients may
induce clinically unapparent damage which may promote pro-
gression of diabetic neuropathy.7 However, the changes
observed here are very small, and need to be investigated in
detail before any clinical relevance can be ascribed.
In LD animals, block duration was significantly prolonged,
while LDI animals had an intermediate increase in block dur-
ation. This finding was expected on the basis of previous
findings. Our results differ in magnitude from our previous
manuscript, in which several tests were used to quantify
motor, deep sensory, and superficial sensory block.11 In com-
parison, our rather crude ‘on/off’ testing for a vestibular reflex
in this study more closely reflects the data obtained by Kroin
and colleagues,10 who used the same method. The main differ-
ence with the latter study is that we used 0.2 ml of 2% lidocaine
as in our previous study,11 whereas Kroin and colleagues used
0.1 ml of 1% lidocaine.10 Several studies have assessed block
duration in a streptozotocin-induced rat model of type I DM,
and while one study found no difference,21 three studies
showed prolonged block duration in diabetic rats.10 22 23 This
latter finding was confirmed by us in the ZDF rat model of
type II DM.11 Recently, two clinical studies described increased
sciatic nerve block duration in diabetic patients.8 9 Therefore,
the evidence strongly indicates that diabetic neuropathy will
prolong the duration of peripheral nerve block. This prolonga-
tion may be caused by pharmacokinetic26 or pharmacody-
namic (e.g. modulation of sodium channels by neuropathy)27
mechanisms, but the respective contributions remain unclear.
Potential clinical implications are to consider the diabetic
nerve ‘more sensitive’ to the effects of local anaesthetics,
and it has been proposed to reduce the dose of local anaes-
thetics when performing nerve blocks for perioperative
analgesia.4 Also, it had been suggested to reduce or omit
epinephrine from peripheral nerve blocks in neuropathic
patients,4 and the results obtained in experimental and clinical
settings would indicate that nerve block duration in diabetic
neuropathy will be prolonged anyway, even without the need
to add adjuvant epinephrine.
Limitations
In the LDI rats, the effects of insulin were not sufficient to cause
glucose levels to be similar to those in control animals, even
though the same dose achieved good glucose control in type
I23 and type II28 models of DM. This may be because insulin
was dosed according to body weight at baseline (10 weeks),
and diabetic animals were substantially heavier at the end of
the experimental period, leading to relative under-dosing
towardsthe end of the experimental period, which is supported
by the increasing blood glucose levels over time in these
animals. Therefore, our insulin regimen was more representa-
tive of loose rather than strict glycaemic control.
In diabetic and control animals, small inflammatory
changes were noted on neurohistopathological investigation
in all groups, which may be explained by repeated stimulation.
Sciatic nerve inflammation after repetitive stimulation, as oc-
curred in our study due to neurophysiological measurements,
has been described in vivo before.29 The timepoint of excision
was chosen on the basis of earlier experiments by our group,
but differ with the timepoint chosen by Kroin and colleagues10
(2 days post-block). The mild changes after block were seen
both in the study by Kroin and colleagues and our study.
A B
Fig3 Neurohistopathology of a representative healthy control nerve (A), and a nerve from a representative diabetic animal, showing focal areas of
acute myelin injury and axonal damage, associated with scattered chronic inflammatory cells (B).
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The ZDF model used by us cannot be extrapolated directly to
the clinical situation. First, the age of the experimental rat is
comparable with that of a young human adult on the basis of
physiological and behavioural parameters.30 However, it
should be noted that we chose the age of our test animals
based on the age at which neuropathy typically develops,
which is around 20 weeks.24 Secondly, interspecies differences
between rats and humans concerning neuropathy and toxicity
of local anaesthetics are unclear. Nevertheless, rodent models
have been used to investigate diabetes and its neuropathy,24
and determine functional and toxicological aspects of regional
anaesthesia in the past.31
Lastly, we attest to the fact that the focus of behavioural
testing after sciatic nerve block was on the motor component
of the nerve block, while DPN profoundly affects sensory func-
tion as well.1 However, in a previous study using the same
model, we obtained comparable prolongations of both motor
and sensory block upon sciatic nerve block.11
Ethical considerations
Animal distress was minimized by conducting all invasive pro-
cedures such as electrophysiology and nerve block under
general anaesthesia, and tissue injury and post-interventional
pain were limited by performing nerve blocks percutaneously
as described by Kroin and collegues.10 However, this approach
may result in a less reliable injection site, and intraneural
injection is possible. A study directly comparing these two
modes of injection found comparable results for both
approaches.10 The same percutaneous approach using thin
needle electrodes was chosen for electrophysiological mea-
surements. To avoid repetitive injections of insulin for the
animals randomized to the late group, we used subcutaneous
implants. To minimize the number of animals used in experi-
ments, we obtained approval to use the heart and the right
sciatic nerve of our test animals for other experiments.
Future perspectives
We describe a novel comprehensive model to investigate toxi-
cological and functional consequences of diabetic neuropathy
in vivo, combining behavioural, electrophysiological, and histo-
pathology methods. Despite lidocaine being the most widely
used local anaesthetic for toxicity research, it has been sug-
gested that longer-acting local anaesthetics such as bupiva-
caine or ropivacaine may be more toxic with respect to
neurohistopathology.10 Investigation of the neurotoxic poten-
tial of long-lasting local anaesthetics such as bupivacaine, and
the value of adjuvants is therefore required.
Conclusions
Our results suggest increased sensitivity of diabetic nerves to
short-acting local anaesthetics without adjuvants in vivo, as
evidenced by prolonged block duration in a rodent type II DM
model with long-standing diabetic neuropathy. This sensitivity
appears to increase with the progression of neuropathy. We
observed very subtle changes suggestive of nerve injury after
nerve block in general, with no correlate in gross behavioural
testing or neurohistopathology, and no specific effect of neur-
opathy. Our results do not support the hypothesis that neur-
opathy due to type II DM increases the risk of nerve injury
after peripheral nerve block.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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